Thanks, with have delays. PH, where Duncan. start regulatory I will we LungFit faced
going Our must quest until we anticipated of XXXX. for CE first but well, fiscal the half approval our Mark postpone year our is
the our first We before similar to and of these our expect faced so submitted this we in beyond confident thus, of goals. do the remain not supplement expansion, issues of In of PMA for the U.S., half yet but have control, have achieving year. end label we delays cardiac calendar both
that we VCAP agree the have our pneumonia safety efficacy per in given to this study, FDA parts an year program, oxide parts of conducted start other respect began studies we with XXXX. our our FDA to we in be continue three studies, adult with patients. and excess believe intend in studies. fourth work which study for million upon allow over the to XXX NO to and the study, closely the XXX summer discussion X,XXX NTM nitric XXX two With should resulted at We protocol quarter studies, calendar These bronchiolitis in of this to to several profile over per along million administrations
mentioned Clean Squeaky we mention times in many to past. the safety have that the data in animals Not
is reported proposed Israeli study. As a we reminder, extremely from this in viral what to pneumonia similar our design study
test treat virus, to who hospitalized virus SARS-CoV-X. any all pneumonia expect any positive We including for and with of variants patients
parts one per in no long-term the infants pneumonia we million Plus, filed We years five have saw NO and the study. from NO adult studies long-term, more seen than acute no some out XXX per and SAEs related million bronchiolitis effects treatment. three XXX to parts to
to high studies dioxide nitrogen with no data manage Our associated our ability concerns treatment. methemoglobinemia long-term of continuing and exposure reflect concentration and
confident are on to build will we We that results. able be these
study present more medical XX than our was Moving multiple in weeks. per million times day patients no by parts delivered home per to for professional XXX at which with NO,
these can as were see by website. XXXX the they Chest presented Meeting at Annual data visiting our You
were no reported. Just no dioxide nitrogen a reminder, methemoglobinemia issues and
a data fast moving support not until of pivotal for possible. forward we study this year to half with patients and these with that working move meet line. forward see the NTM do second as we believe fiscal the our shorten We time, XXXX. FDA or At beginning as to this will look study We time
COPD in be pilot with winter. underlying this conducted not Our study patients coming will
no. in of FDA immediate We priorities in the work are to to with start LungFit begin will of we the varied will and look calendar PH quarter addressing continue XXXX. our VCAP fourth to and applications
over releasing last strong. since months raised money human ongoing the XX Phase that clinical Xa current calendar Moving later is has very the our data been this we on Progress with topline be year. to Beyond will belief The Cancer. study
publication first with another is expected Our later out year. this
conferences Our preclinical when to shown therapy we in several team at of have added year we animals doubling is a quite medical already anti-PD-X anti-PD-X our this alone. to active and therapy data compared with expected survival UNO
also renowned our with Choy additions of the has of as world Gavin Dr. Stanford expanded Beyond Dirbas Pegram, at been team recent Dr. both Cancer to COO Mark and oncologists SAB. hiring The Fred and the
stay for patent for our this Please later detail first tuned year. and technology the for these beyondcanter.com accomplishments addition, on visit more issued. all of In was
XX, for Officer, now provide to Chief Doug? the our will over to ended results December quarter the an I Doug financial overview fiscal XXXX. call turn Larson, Financial of our